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Abstract
Fields such as, diagnostic testing, biotherapeutics, drug development and toxicology 
among others, center on the premise of searching through many specimens for a rare event. 
Scientists in the business of “searching for a needle in a haystack” may greatly benefit from 
the use of group screening design strategies.  Group screening, where specimens are 
composited into pools with each pool being tested for the presence of the event, can be 
much more cost efficient than testing each individual specimen.  A number of group 
screening designs have been proposed in the literature. Incomplete block screening designs 
are described here and compared with other group screening designs.  It is shown under 
certain conditions, that incomplete block screening designs can provide nearly a 90% cost 
saving compared to other group screening designs such as when prevalence is 0.001 and 
screening 3876 specimens with an ICB-sequential design vs a Dorfman design.  In other 
cases, previous group screening designs are shown to be most efficient.  Overall, when 
prevalence is small (≤0.05) group screening designs are shown to be quite cost effective at 
screening a large number of specimens and in general there is no one design that is best in 
all situations. 
Keywords: Group testing, multistage, pooling, prevalence
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Introduction
The development of new technologies that allow for rapid and multiplexed diagnosis 
and screening tests represent promising methods for quickly detecting animal and plant 
infectious diseases, tumor-derived biomarkers, plant seed genetic purity, food safety, 
environmental pest management and other types of molecular polymorphisms with 
important implications ranging from agriculture to biosecurity. (1) - (2)  However, the 
incorporation of powerful experimental design strategies to further increase the potential of 
many high-throughput molecular platforms now available has received little attention. Such 
is the case of group screening designs, which can have a significant impact in the cost and 
efficiency of experiments where a positive event is rare and samples sizes are large. 
To illustrate the usefulness of a group screening design, assume a plant geneticist 
wants to evaluate 455 plant genotypes for the presence of a particular transposition event 
where fewer than 1% are expected to contain the event.  Expensive and time consuming 
DNA extractions and PCR-based identification techniques must be used to identify the plant 
carrying the transposition event.  In order to reduce costs, the geneticist would like to pool 
the DNA of groups of plants where extractions are conducted only on the pools.  Plants in 
any pool that does not contain the particular transposition event will be eliminated from 
further consideration.  Plants in positive pools could either be tested individually or in 
smaller pools.   Using such a group screening strategy will generally result in fewer tests 
needed to identify all positive plants compared to separately testing all 455 plants. (3) 
Two different group screening designs illustrate the strategy for this particular study.  
A simple approach, assuming sufficient test sensitivity, would be to composite all 455 plants 
in one pool and if the pool tested negative, clear all 455 plants of containing the event, while 
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if the pool tested positive, test all the 455 individually.  However, the expected number of 
tests would likely be too large except for cases where the probability of an event was much 
smaller than 1%.    Another approach, proposed by Dorfman (4) would be to divide the 455 
specimens into m pools, (say for example 35 pools of 13 plants each) where each specimen 
in a pool would be retested if the pool tested positive.  Dorfman (4) demonstrated that this 
scheme could result in cost savings up to 80% over testing all specimens separately 
In general, group screening of b specimens (plants in the example) proceeds by 
assigning specimens to pools using some design, clearing all specimens in negative pools 
and further testing specimens in positive pools either separately or again in batch .  
Phatarfod and Sudbury (5) proposed arranging specimens in a square array with b=n2 and 
pooling each of n rows and n columns, giving 2n pools, which improved efficiency over the 
Dorfman approach in some situations while Hudgen and Kim (6) considered optimal 
configurations of square arrays. Sudbury (7) compared efficiencies between two-
dimensional arrays and selection designs and found selection designs to be at least as 
efficient as two-way arrays for a range of different batch sizes.  Berger et al. (8) proposed 
higher-way array pooling and demonstrated that these methods could further improve 
efficiency.   Kim and Hudgens (9) showed that three-dimensional array based methods in the 
presence of test error are more precise than two-dimensional arrays and that four-way and 
higher arrays do not lead to large gains in efficiency.  A number of multi-stage and 
sequential schemes have been proposed where most have used the Dorfman group screening 
design as an initial design (10)- (11).
In this work, we propose using unreduced incomplete block designs for developing 
group screening designs and show that under some conditions, these designs perform better 
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than previously proposed methods when the probability that an individual specimen is 
positive is small (≤0.05).  Sudbury (7) considered unreduced incomplete block group 
screening designs, which he termed selection designs, but did not consider expected number 
of tests to determine all positive specimens, compare them with designs other than 2-way 
arrays and did not consider sequential applications of these designs.   Other types of 
incomplete block designs have been proposed for group screening designs but generally for 
different purposes. Redman and King (12) proposed using balanced and partially balanced 
incomplete block designs for group screening when quantitative response was available for 
each pool. Bush et al. (13) proposed using special types of incomplete block designs called 
t-complete designs useful when the number of defectives is known before experimentation 
which is unlikely in many applications. Balding and Torney (14) proposed using various 
types of incomplete block designs in a non-adaptive setting where specimens were not 
retested. Du and Hwang (15) described the theory and general properties of using 
incomplete block designs as group screening designs. Here, we first show how to construct 
an unreduced incomplete block group screening  (ICB) design and in general how these 
designs are based on unreduced incomplete block designs, then describe the data analysis 
and how expected sample sizes may be determined.   We then compare several different 
group screening designs with the designs proposed in this paper and finish with some 
discussion.   
Design Construction
The fundamental idea of an ICB group screening design is to (1) determine all 
possible ways an individual specimen can be assigned to k out of t pools and (2) add a single 
Page 5 of 31
John Wiley & Sons
Biotechnology Progress
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6
pool that contains all specimens.  This design results in each specimen being tested in k+1 
pools.   For example, assume 10 =  specimens are to be tested with a total of 6 (5+1) 
5
2
   
pools where each specimen is to be present in 3 (2+1) pools.  First, determine all possible 
ways that a specimen can be assigned to 2 of 5 pools resulting in Pools 1 through 5 of Table 
1.  Then add a final pool with all specimens which is the 6th pool in Table 1.  Finally, 
randomize the specimen numbers in Table 1 to actual specimens.  In Table 1, specimen 1 is 
in pools 1, 2 and 6 while specimen 9 is in pools 3, 5 and 6.   In the data analysis, the 
sequence of positive pools can identify which specimen is positive.  For example, if pools 1, 
2 and 6 are positive, then specimen one is uniquely identified as positive while all others are 
negative.    With this particular design, up to two positive specimens can be detected 
although not uniquely.  For example, if all pools are positive except 3, then either (i) 
specimens 1 and 10 or (ii) specimens 4 and 6 or (iii) specimens 3 and 7 must be positive, 
while the others are negative.  
 In general, assume n pools are to be used to screen b =  specimens (b n) for the 
   
t
k
presence of a particular attribute where t=n-1 and each specimen is assigned to k+1 pools.  
Each pool, excluding the final pool containing all specimens, will contain  
1
1
   
t
k
specimens.  Also, assume that within the population, the chances that any individual 
specimen is positive is quite small (≤ 0.05) and that there are no dilution,  interaction effects 
or errors in the testing technique.   Then a negative pool response eliminates those 
specimens in the pool from further testing.   This type of group screening design can be 
shown to be obtained from an unreduced incomplete block design (ICB) where the b 
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7
specimens form the incomplete blocks and the first t-1 pools represent the treatments where 
there are k treatments in each block.  For example the first 5 pools in Table 1 are based on 
an unreduced incomplete block design with 5= t-1 treatments in 10= b incomplete blocks of 
size 2=k, where the 6th pool is augmented to the other 5 pools.  Each of the first 5 pools will 
contain  = 4 specimens.  
5 1
2 1
   
This construction method is general in that the approach may be used with any 
unreduced incomplete block design (ICB) (ie. any t and k where k<t) however, the approach 
is limited to the number of test specimens where b= .  Any incomplete block design 
t
k
   
with t treatments and k units per block (bib or not, unreduced or not) could be used to 
identify a group screening design, however the properties of these designs have not be 
considered.   As an example, modifying the design in Table 1 to screen 8 instead of 10 
specimens by eliminating specimens (blocks) 9 and 10 results in an ICB screening design 
based on an imbalanced incomplete block design which has unknown properties regarding 
expected sample size (see below).  
Data Analysis
The resulting data from an ICB group screening experiment will be a plus (+) or 
minus (–) for every pool where a + for a pool indicates that at least one of the specimens in 
that pool is positive and a – if the pool contained no positive specimens. Specifically the 
results will be a n vector of pluses (+) and minuses (–) and data analysis is based on this 
response vector.  The idea is to retest those specimens that could be contributing to the 
particular response vector or alternatively, eliminate those specimens from further testing 
which could not.
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8
Assume n pools are to be used to screen b=  specimens.  The number of positive 
t
k
   
specimens will depend on the particular response vector. 
All pools are negative.  If all elements are negative in the response vector, then no 
specimens are positive and no more testing is required.  Note that it is not possible to have 
between one and k positive elements in the response vector, since if a specimen is positive, 
at least k+1 positive values will result since each specimen is in k+1 pools.  If there are 
between one and k positives, then the assumptions of no error, dilution or interaction effects 
may be incorrect. 
Exactly one negative. If there is exactly one – sign present in the response vector, 
then there are  different specimens (or blocks) that could have contributed to the t 1t
k
   
positive signs in the response vector and these specimens should be retested.  Specimens are 
retested if they are in any of the t pools that test d positive, or alternatively, any specimen is 
eliminated from further testing if it is only contained in those pools that test negative.   
Exactly two negatives. If there are exactly two – signs in the response vector, then 
  specimens (or blocks) may be contributing to the response vector.  Specimens are 
2t
k
   
retested if they are in any one of the t-1 pools that tested positive.   
General Case.   If a group screening design is based on an unreduced incomplete 
block design (t,k) and if there are p – signs (0 <  p  t - k) in the response vector, then 
 specimens could be contributing to the response and should be retested.  Specimens 
t p
k
   
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are retested if they are in any of the t-p+1 pools that tested positive, or alternatively, any 
specimen is eliminated from further testing if it is contained in all pools that test negative. 
Expected Sample Size
An ICB group screening design will be useful if it reduces the number of pools (or 
samples) needed compared to other group screening designs.  To determine the expected 
sample size (ie, the expected number of retests plus the initial number of pools), assume that 
(i) specimens are independent and randomly sampled from the population of interest and the 
probability that any particular specimen is negative is q, (ii) there are b =  specimens 
t
k
   
and n pools (or t =n-1), where each specimen will be tested in k+1 pools and (iii) one of two 
different follow-up schemes will be used with the specimens to be retested:  (a) either tested 
separately or (b) all retested using additional ICB group screening designs.
Retested specimens tested separately. To determine the expected number of 
retests, we need the probability distribution of the number of retests:
Number of retests   0                         …      
k
k
   
( 1)t t k
k
     
( 2)t t k
k
     
1t
k
   
t
k
   
Probability             qb   qb-1(1-q)           f1(q)                       f2(q)         …    ft-k-1(q)   ft-k(q)
b
1
   
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10
The expected number of retests is computed in the usual way: E(no. of retests) = ∑(no. of 
retests)(probability).  
The idea of this probability distribution is that the binomial distribution of the 
number of positive specimens out of b specimens will be ‘broken-up’ into the needed 
probabilities above.  Here,  fu(q)= Cu1 qb-2(1-q)2 + Cu2 qb-3(1-q)3+ Cu3 qb-4(1-q)4 … 
(u=1,…,t-k),
Cu1 =  (u=1,…,k) 2
k t k t
k u u k
          
 Cuv =     (v=2,….b-1) , 1
1
( )
( ) ( 1)
( )
t k
j v
j
k j t k j
C vI j u v
j k u k j k u



                    
where  Cu1 and/or Cuv are defined as 0 if any combination  in their definition has either 
x
z
   
x<0, z<0, or x<z.  Also, by definition of the binomial distribution  for 
1 1
t k
uv
u
b
C
v


    
v=1,…,b-1.  See Appendix for proof.   
As an example, the design with b=10 (t=5,k=2) has the following probability distribution of 
the number of retests and expected number of retests.  
Number of retests                                                   Probability
           0                                                                          q10
= 1                                           q9(1-q)  
2
2
   
10
1
   
                                                                  
 = 3              30q8(1-q)2 + 10q7(1-q)3 
3
2
   
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 = 6             15 q8(1-q)2 +80q7(1-q)3 + 75 q6(1-q)4  + 30 q5(1-q)5 +   5q4(1-q)6
4
2
   
= 10                                30q7(1-q)3 + 135 q6(1-q)4 + 222 q5(1-q)5 + 205q4(1-q)6                
5
2
   
                                                    + 120q3(1-q)7 +  45q2(1-q)8  + 10 q1(1-q) 9+(1-q)10
               
Using the definition of expected value and the probability distribution in the display above, 
the expected number of retests when q=0.999 can be shown to be 0.01 and the expected 
sample size would be 6.01.  
Retested specimens tested in follow-up ICB group screening designs. Using 
concepts from unreduced incomplete block designs, the number of specimens to be retested 
given any particular response vector from the analysis of the initial design, may be 
expressed as a combination.  If the initial design has parameters (t,k) and there are p  – signs 
(p 0) in the response vector, specimens must be retested, where the specific 
t - p
k
   
specimens to be retested are those that are in the pools that tested positive.    These  
t - p
k
   
specimens can be tested in a follow-up ICB group screening design with ‘new’ parameters 
(t-p, k) (or (t-p,t-p-k)  by symmetry of binomial coefficients).   This follow-up design is 
likely to have a much smaller expected sample size than testing all of the  specimens.  
t - p
k
   
For example, if the initial design has 462 specimens (t=11, k=5)  and there are p=2 – signs 
in the response vector, there will be 126 specimens to be retested.  These 126 specimens are 
then tested using a t=9,k=5 ICB group screening design.   Depending on the size of q, this 
approach may result in a considerable savings over separately testing all 126 specimens.   If 
q=0.999, then the expected number of retests is 0.37 and the expected total number of tests 
Page 11 of 31
John Wiley & Sons
Biotechnology Progress
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12
for the t=9, k=5 design is 10.37 vs 126.  This testing with follow-up ICB group screening 
designs may be repeated successively in a multi-stage approach which could reduce the 
expected sample size even further.  For example, if the initial design is (t=11,k=5) and p=2 
– signs result, a second stage follow-up design with t=9 and k=5 could be used to test the 
remaining 126 specimens.  If with the second stage, 2 – signs result, then the 21 specimens 
to be retested would be evaluated with a t=7, k=5 design.  If the third stage resulted in a 
single – sign,  the just one specimen would be retested for a total of 11+9+7+1 = 28 tests in 
all.
To use the proposed ICB designs, a researcher would first establish the number of 
specimens to be screened and then construct the appropriate number of pools and analyze 
results as described above.   For example, assume a researcher has 1365 specimens to 
evaluate, that q=0.999 in the population and wants to minimize the expected number of 
required pools.  Given Table 2, use of an ICB design shows considerable cost savings in 
terms of the expected number of pools necessary (eg., 18 fixed ICB (ICB-F); vs 86 
Dorfman; 75 Two-way; 40 Three-way; and 1017 single pool).  
For a more realistic example with parameters not given in Table 2, consider a 
toxicology project in protein therapeutics, where a cell-line derived through cloning is used 
for the purposes of synthesizing therapeutic protein material for toxicology testing and, 
subsequently, for clinical studies. Assume the identification of the “right” clone is key to 
this research and that there is a large population of stably transfected cell lines, each 
expressing a different antibody type. The goal is to identify the antibody that best targets a 
very specific epitope (i.e., selective targeting). In this case, this is a line that can be 
identified through a binary response, e.g., above vs below a response threshold. Assume that 
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this is a rare event, e.g., it occurs 1 out of every 1,000 cell lines tested (q=0.999), and that 
there are no dilution, interaction effects or errors in the testing technique.  Suppose the 
researcher has 4560 cell-lines available for testing. Instead of screening each clone 
individually and investing resources into at least 48 96-well ELISA plates and reagents, the 
researcher could use the scenario described in Figure 1.
Figure 1. Scenario where dilution effects are negligible. 
Set up an ICB-fixed design with t = 96, k = 2 and b = 4560 cell-line clones 
(specimens).  The initial number of pools for the first stage would be 97 (i.e., t + 1) which 
implies that first a single pool that contains all clones tests positive.  This of course assumes 
the single pool that contains all clones is actually feasible, but it is not absolutely necessary.  
The expected number of tests after the first 97 pools is a function of prevalence (1-q) of the 
specific antibody in the population being tested.  Positive clones indicated from the first step 
Page 13 of 31
John Wiley & Sons
Biotechnology Progress
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14
could be tested individually, as assumed by ICB-F fixed design or setup in another ICB-S 
sequential design in order to continue to minimize costs.  In this example, the ICB-F design 
has expected sample size of 99 pools which is considerably smaller than the expected 
samples sizes of the Dorfman, 2-way and 3-way which are 288, 157 and 145, respectively.  
The expected savings are approximately 98% of the cost of ELISA screening reagents (e.g., 
one ELISA plate for screening 96 pools vs 48 96 well ELISA plates if the researcher were to 
screen individual samples). We chose to omit the need for positive and negative controls in 
the screening plate for simplicity and focused instead on delivering the main point, 
applicability.  
The example described in Figure 1 serves several purposes. First, the scenario is 
outside of the options listed in Table 2. That is, the use of pooling designs described above 
is by no means limited to the parameters shown on Table 2. ICB and other designs can be 
applied to any number of samples (emphasis on the word “any”). Table 2 has the main 
purpose of comparing design efficiencies under the same parameters and no one design is 
superior all the time, although, all designs offer different degrees of resource savings 
compared to the option of individual specimen testing (except for the 1-pool design in some 
instances). Second, the use of b = 4560 clones above serves the purpose of exemplifying a 
number that fits common sample-handling platforms (i.e., 96-well plates) to ease handling 
of samples.  This approach can be extended to accommodate 384 well-plates, in which case   
t = 384, k = 2 and b = 73,536 results in a scenario where a researcher could screen a total of 
73,536 clones using only t + 1 (385) pools.  Here all pools, other than the first pool that 
contains all specimens, would contain 383 specimens, and ultimately each pool would be 
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assigned to a well on a single 384-well ELISA plate (if screening t pools only).  In other 
words, these designs are flexible and could easily be scaled up.
 
Comparison with other designs
The goal of most group screening programs is to identify the positive specimens 
using a minimum number of pools.  In comparing designs, we assume that cost is of primary 
importance and that the preferred design has the smallest expected sample size (i.e., the 
smallest expected number of retests + initial number of pools).  Two types of ICB group 
screening designs will be used: (1) fixed designs where retested specimens are tested 
separately and (2) sequential designs where retested specimens are tested in a single follow-
up ICB group screening design.   For the sequential designs, the expected sample sizes for 
the follow-up design will be based on the minimum possible q that could yield a given 
number of – signs in the response vector of the initial design.  For example, for an initial 
design with t=11, k=5 where there are p=2 – signs in the response vector, the minimum 
number of positive specimens that could give such a response is 2 (9/5 or (t-p)/k rounded 
up) giving an estimated q = 1 – 2/462 where there are b = =462 specimens to be tested.  
11
5
   
This q is then used to estimate the expected sample size in the t=9, k=5 ICB follow-up 
design.  The multi-stage approach with multiple successive follow-up ICB designs, was 
initially considered, but expected sample sizes differed only slightly from the sequential 
designs (data not shown) and was not be included.  
A number of different group screening schemes have been proposed in the literature 
where most have been based on either the one-way (4) or two-way array designs. (16), (17), 
(5), (18)  An extension of the two-way design to a multi-way array (8) shows promise and 
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will be considered.   Also, since q is assumed large, a single pool of all the specimens is the 
simplest possible group screening design, since if the test for this single pool is negative, no 
further testing is needed.  The expected sample sizes will be determined for the two types of 
ICB designs (fixed: ICB-F, and sequential: ICB-S) the Dorfman approach with optimal pool 
size as described in Feller, (19) (page 240, k=(1-q)-.5), the two-way array (5), the three-way 
array (3P method from Berger et al. (8) ) and the single pool, where all specimens are tested 
individually if the single, all specimen pool is positive.  The pool sizes for the two-way and 
three-way array designs were approximated as b1/2 and b1/3 respectively, to enable direct 
comparison with the ICB designs.   
Expected sample sizes for all the methods for a range of specimen sizes with q 
ranging from 0.95 to 0.999 and an initial number of ICB pools of 8, 12, 16 and 20 (including 
the single pool) are given in Tables 2.  With all methods, the expected number of tests 
decreased as q increased showing increased efficiency as the attribute became rarer.  The 
single initial pool design nearly always had the largest expected sample size indicating that 
when a positive event is rare (q   0.95), this method can be expected to be the most costly 
among the methods evaluated.  The ICB fixed and sequential ICB designs were nearly 
identical in most cases meaning for these values of q, the sequential approach had little 
effect.  In a majority of the cases, the Dorfman design had the smallest expected sample size 
which was based on Feller (19) (p240, 2b(1-q)).  However, for the middle ranges of the 
number of specimens (b) for a given q (e.g. q=0.95, 55 ≤ b ≤ 171;  q=0.99, 105 ≤ b ≤ 455;  
q=0.999, 330 ≤ b ≤ 3876), the ICB design had the smallest sample size.  For the most part, 
the 2-way and 3-way designs did not perform as well, yet there were a few cases where the 
2-way did best and one where the 3-way did best.   
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The Dorfman, two-way and three-way designs have been compared in previous work 
but the ICB designs proposed here have not been compared with previous designs.  Berger 
et al. (8) evaluated efficiency of two- and three-way arrays and compared efficiencies to 
upper bounds on multi-stage strategies and showed the three-way array to be more efficient 
than the two-way for large values of q.  Phatarfod and Sudbury (5) compared efficiencies of 
the Dorfman approach, the two-way array and a modified two-way array and concluded that 
the two-way array was more efficient than the Dorfman approach in all cases considered.  
Our results were similar to Berger et al. (8) for q=0.999  in that the three-way array was 
more efficient than the two-way in the majority of cases, but we found the 2-way method 
more efficient than the 3-way in the majority of the remaining cases.  However, contrary to  
Phatafod and Sudbury, (5) we found the Dorfman design to be more efficient than the two-
array.  The reason our results differed was likely because we did not ‘optimize’ pool size for 
the two- and three-way arrays.  Optimizing pool size for two- and three-way array designs is 
often not appropriate since in most screening programs, the number of specimens to be 
screened is known before work begins as opposed to identifying the number of specimens to 
be screened as a function of q.  In addition, assuming b and q are given allowed direct 
comparison with the ICB designs and the other methods.  
In most applications, the number of specimens (b) will be known and the choice of 
the number of pools (t) (excluding the all specimen pool) and the number of specimens per 
pool  will be of interest.  When b is not in Table 2, a reasonable design can be found.  
1
1
   
t
k
As a specific example, assume there are 80 specimens to be evaluated for a prevalence of 
0.05 (1-q) and the intent is to determine approximate values of the number of pools and the 
number of specimens per pool for the initial design.  From Table 2, with q=0.95, there is no 
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b=80 ICB design, but there are ICB-F designs for b=55 and b=105 with expected sample 
sizes of 15 and 20 with 10 and 14 specimens per pool.  A reasonable approximation of the 
number of pools (t) is 13 which may be found by finding t such that 80   = 78.  The t
2
   
precise initial design would have 78 specimens in an ICB design with 13 pools (t=13), 12 
specimens per pool ( =12) and an additional 2 specimen pool of the 79th and 80th 
13 1
2 1
   
specimens.   This design will have an approximate expected number of pools to be 17.5 (1/2 
way between 15 and 20).  As a comparison with the other designs: (1) the optimal Dorfman 
design will have k  5 with t=16 and with an overall expected sample size of 36 
(specifically, from Feller (1968), k  1/(1-q) = 1/.2235  5;  t=80/5=16 and expected 
sample size of 2b*.2235=160*.2235=36); (2)   the approximately optimal 2-way array 
design will have 9 pools with 9 specimens each, ie 9  b1/2 where b=80 with an interpolated 
expected number of samples of 29; (3) the approximately optimal 3-way array will have 
k=801/34, (ie 4-4x4 arrays) with a reasonable initial design of a 5 4x4 3-way array with an 
interpolated expected number of samples of 38.  In the three designs being compared to the 
ICB-F design, each has a larger expected sample size, some by a considerable margin.  
The same type of approach can be used to obtain reasonable ICB designs for all 
values of b that fall within the range of Table 2.  For a b value that is between two b values 
from Table 2 that have the ICB-F designs with the smallest expected sample sizes, the 
approximate ICB-F design as described above should be more efficient than any of the other 
designs.  For example, when q=0.999 and 330  b  3876, the approximate ICB-F design 
would appear to be preferred since the expected sample size at b=330 is 12 and at b=3876, 
the expected sample size is 56, both of which are smaller than all other comparable designs.   
Page 18 of 31
John Wiley & Sons
Biotechnology Progress
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19
But it must be remembered that all of the above comparisons are only approximations and 
further research into the properties of these designs beyond those given in Table 2 is needed.  
A major assumption is that there are no testing errors.  ICB group screening designs 
may be still useful in the presence of one false negative or one false positive pool in the 
initial experiment, although more testing likely will be necessary.  If it is unknown that an r 
specimen pool is a false negative and k+j’  (j’=1,…,t-k+1) positive pools are observed, then 
the response vector will make it appear that =  specific specimens should 
t p
k
   
' 1k j
k
    
be retested.  However, upon retesting these specific specimens, none will be positive, and it 
can be shown that another set of (t-k-(j’-1)) specimens should be retested thus 
' 1
1
k j
k
    
increasing the expected sample size.   Similarly, if it is unknown that an r specimen pool is a 
false positive and k+j’  (j’=0,…,t-k+1) positive pools are observed, it will appear that a set 
of =  specific specimens should be retested, however only specimens 
t p
k
   
' 1k j
k
    
from a subset of  specimens can truly be contributing to the response vector.  
' 2k j
k
    
Thus, a single false positive in the initial experiment will increase retesting and increase the 
expected sample size.  Similar results can be established for more than one false positive or 
negative, but the important issue is that the cost savings ability of the ICB group screening 
designs decreases as testing error increases. Du and Hwang (15) (Theorem 3.1.2) also 
demonstrate that when there is at most one positive specimen, an incomplete block group 
screening design can tolerate a single false positive or false negative pool.   
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When it is important to screen a large number of specimens and the chances are small 
(<0.001) that any one specimen is positive for the attribute of interest, the three-way array 
and the ICB sequential designs show a considerable cost savings over the two most 
commonly used group screening designs: the Dorfman approach and the two-way array.   
The ICB sequential design can give nearly a 90% and 80% savings over the Dorfman and 
the three-way array approaches respectively and up to a 70% savings over the three-way 
array approach in some cases.   In other cases, the three-way design can show large savings 
over the Dorfman, two-way and ICB designs.  Du and Hwang (15) give extensive 
description of the properties of two-way and three-way designs.     
Discussion
We chose to highlight a relatively simple scenario with the example of Figure 1 to 
hopefully deliver a clear picture of the potential efficiencies and cost savings of these 
designs. However, we are well aware of the several (sometimes unrealistic) assumptions 
used. Perhaps, the most critical assumption is the absence of dilution effects when using 
pools of hundreds of samples. The power of these designs will depend heavily on the 
robustness of technology available for screening and there will be some instances where 
threshold parameters will have to be experimentally defined along with variance 
quantification. It is likely that before adopting an efficient pool screening design 
methodology, a lab may need to invest resources to identify technology limitations and 
quantify technical variation.  However, such investments can have large payoffs since these 
designs can yield great efficiencies and cost savings and more importantly are backed up by 
a sound statistical framework. When using ICB designs, the randomization of samples as 
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well as the actual pool design to be used by the bench scientist can be easily obtained with 
an R program (see appendix ). 
The use of pooling designs can extend to other areas of research.  Discovery of rare 
functional variants: Group screening designs can be used to decrease the cost of sequencing 
runs in experiments estimating the impact of minor allele frequency (MAF) on detection 
capability of functional variants when using pools of individuals. Jakaitiene et al. (20) 
showed a novel methodology using pooled patient samples that allowed an efficient increase 
in sample size by sequencing pools of individuals. This, tied together with their clever 
multi-reference (multi-pool as reference) framework and beta-binomial models allowed 
them to improve the accuracy of identification of neuromuscular disorder mutations, and it 
also allowed for the discovery of novel rare variants (Jakaitiene et al. (20)). Their multi-
reference framework can be further extended to make use of ICB group screening designs to 
increase the power of the reference pools by determining the optimal number of pools to be 
used in an experiment, so as to maximize efficiency and detection capabilities. Groups of 
pools using ICB group screening designs can also be partitioned across multiple sequencing 
runs and the independent runs can be analyzed together as a meta-analysis (Wang et al. 
(21)). The potential for ICB group screening designs in the detection of rare causative 
disease alleles can have a huge impact in the field of epidemiology where the screening of 
vast number of samples is the nature of this field (Wang et al. (21)).
Recent discoveries in gene editing (CRISPR-Cas technology) are potential tools 
adapted to on-field deployable diagnostic tests. The CRISPR-Cas gene editing system has 
been further modified to allow for the rapid identification of very specific viral infections in 
samples that resemble real life human samples (Chen et al. (22); Chertow (23); Gootenberg 
Page 21 of 31
John Wiley & Sons
Biotechnology Progress
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
22
et al. (24); Myhrvold et al. (25)). The Cas13 system adapted into the SHERLOCK (specific 
high-sensitivity enzymatic reporter unlocking) platform, together with HUDSON (heating 
unextracted diagnostic samples to obliterate nucleases, an approach to make detection of 
nucleic acids rapid and direct) have been shown to hold great promise for the rapid, precise 
and effective identification of infected patients with single or multiple virus biotypes 
(Myhrvold et al. (25)). The key characteristics of these optimized systems are the 
instrument-free and fast-paced methods possible. The authors engage in a discussion that 
highlights the use of this technology in parts of the world where diagnostic testing is often 
cost-prohibitive and not used (Chen et al. (22); Chertow, (23); Gootenberg et al. (24); 
Myhrvold et al. (25)). If such a postulate is true and if we are to strive to make new 
technologies available to underdeveloped regions in the world, then we must seriously 
explore the possibilities of incorporating efficient group screening designs, based on sound 
statistical foundations, in order to substantially bring down the per-sample cost to truly 
realize this technology’s promise.
Conclusion
Rapid and multiplexed diagnosis and screening tests can be productively applied in a 
multitude of areas such as drug discovery, precision oncology, cancer immunotherapy,  gene 
editing,  high-throughput sequencing, government funded test screening and large scale 
genetic interaction studies to name a few. The search for the “needle in the haystack” is the 
rule and not the exception in many scientific disciplines. The hunt of rare events has 
prompted a special focus to the dissemination of knowledge in drug development and 
related areas and we hope this work contributes to discussion (Domach (26)).  It is clear that 
there are many technical challenges of current screening platforms and consequently, sound 
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statistical experimental design becomes imperative and not a mere formal nuance.  Group 
screening strategies to target a low frequency (rare) event, can be productively applied to 
many of these areas with important impacts on areas ranging from agriculture to biosecurity 
and human health. The different group screening designs proposed above assume that 
variation in the specific technique can be controlled to a reasonable level resulting in 
adequate sensitivity and specificity.  It is important as we move forward with technology 
dictating the research that we conduct, to intelligently use efficient and precise statistical 
tools such as group screening designs.    
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 Table 1. Small ICB group screening design with 10 specimens and 6 pools 
Pool  |   -----------------------------------Specimen---------------------------------------
1 2 3 4 5 6 7 8 9 10
--------------------------------------------------------------------------------------------------
1 + + + +
2 + + + +
3 + + + +
4 + + + +
5 + + + +
6 + + + + + + + + + +
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Table 2.  Expected sample sizes for six group screening designs with the probability that a 
specimen fails to contain the attribute of interest (q) of 0.95, 0.99, 0.999, the number of 
specimens tested (b), an initial number of pools in the ICB design (i_pools) of 8, 12, 16, 20 and
specimens per pool (spp). 
_________________________________________________________________
q b i_pools spp t k  ICB-S ICB-F Dorf 2-way 3-way 1-pool
0.95 21 8    6 7 2 8 9 9 9 10 14
0.95 21 8   15 7 5 12 12 9 9 10 14
0.95 35 8   15 7 3 11 13 16 12 15 29
0.95 35 8   20 7 4 15 16 16 12 15 29
0.95 55 12   10 11 2 13 15 25 20 23 52
0.95 105 16   14 15 2 18 22 47 38 53 105
0.95 165 12   45 11 3 79 92 74 57 102 165
0.95 171 20   18 19 2 22 33 76 68 108 171
0.95 330 12  120 11 4 335 336 148 156 275 330
0.95 455 16   91 15 3 414 424 203 236 417 455
0.95 462 12  210 11 5 474 474 207 236 425 462
0.95 969 20  153 19 3 928 984 433 673 980 969
0.95 1365 16  364 15 4 1365 1381 610 993 1391 1365
0.95 3003 16 1001 15 5 3003 2999 1343 2671 3046 3003
0.95 3876 20  816 19 4 3876 3876 1733 3655 3923 3876
0.95 11628 20 3060 19 5 11628 11628 5200 11569 11696 11628
0.99 21 8    6 7 2 8 8 4 8 9 5
0.99 21 8   15 7 5 8 8 4 8 9 5
0.99 35 8   15 7 3 8 8 7 10 10 11
0.99 35 8   20 7 4 9 9 7 10 10 11
0.99 55 12   10 11 2 12 12 11 15 12 24
0.99 105 16   14 15 2 16 17 21 22 17 68
0.99 165 12   45 11 3 13 14 33 27 24 134
0.99 171 20   18 19 2 21 21 34 30 24 140
0.99 330 12  120 11 4 48 56 66 47 49 318
0.99 455 16   91 15 3 22 32 91 61 78 450
0.99 462 12  210 11 5 210 222 92 61 80 458
0.99 969 20  153 19 3 61 124 194 136 293 969
0.99 1365 16  364 15 4 998 1038 273 198 549 1365
0.99 3003 16 1001 15 5 2973 3017 601 629 2084 3003
0.99 3876 20  816 19 4 2403 3879 775 962 3041 3876
0.99 11628 20 3060 19 5 11628 8766 2326 5197 11497 11628
0.999 21 8    6 7 2 8 8 1 8 8 1
0.999 21 8   15 7 5 8 8 1 8 8 1
0.999 35 8   15 7 3 8 8 2 10 10 2
0.999 35 8   20 7 4 8 8 2 10 10 2
0.999 55 12   10 11 2 12 12 3 14 11 4
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0.999 105 16   14 15 2 16 16 7 20 14 11
0.999 165 12   45 11 3 12 12 10 24 17 26
0.999 171 20   18 19 2 20 20 11 26 17 28
0.999 330 12  120 11 4 12 12 21 36 21 94
0.999 455 16   91 15 3 16 16 29 43 24 167
0.999 462 12  210 11 5 13 13 29 43 24 172
0.999 969 20  153 19 3 21 21 61 64 33 602
0.999 1365 16  364 15 4 18 18 86 75 40 1017
0.999 3003 16 1001 15 5 118 144 190 119 80 2854
0.999 3876 20  816 19 4 32 56 245 141 113 3796
0.999 11628 20 3060 19 5 5913 6257 735 341 935 11628
__________________________________________________________________________
t=no treatments in incomplete block;  k=block size; ICB-S =expected sample size using unreduced 
ICB with sequential first follow-up using unreduced incomplete block (ICB) design; ICB-F  
=expected sample size using fixed unreduced incomplete block (ICB) design; Dorf. = Dorfman 
expected sample size using Dorfman one-way design using optimal pool size from Feller (1968); 2-
way   = exp. sample size using two-way square array where a side =square root (b); 3-way = exp. 
sample size using Berger et al. 3-way array design with pool size = b** (1/3);   1-Pool = exp. sample 
size using a single pool and testing each specimen if pool is positive.
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Appendix
Derivation of Cu1 and/or Cuv  coefficients
Proof:  The Cu1 coefficients of the qb-2(1-q)2 terms are obtained by considering pairs of 
blocks and determining how many pairs are possible for a given number of – signs in the 
response vector.  For any particular block that is to be paired with another block, there are 
 different possible pairs of blocks with j’(j’=0,…,k-1) treatments in common in 
' '
k t k
j k j
      
both blocks meaning there will be t+j’-2k  – signs in the response vector.  The total number 
of different possible pairs for a given number of common treatments is obtained by 
multiplying   by  since there are blocks where each pair would be 
' '
k t k
j k j
       2
t
k
    
t
k
   
counted twice without division by 2.  
The Cuv (v 1) coefficients are based on an extension of the concept from the Cu1 
coefficients and are developed as recursive functions of Cu,v-1. For any given set of v-1 
blocks with k’ treatments (k’ k) present in the set, there will be   different  ' '
' '
k t k
j k j
      
possible sets of v blocks with j’ treatments in common between the added block and the 
given set of v-1 blocks, except when all j’ treatments are from the k’ treatments (i.e. j’=k), in 
which case, the number of different possible sets will be reduced by v-1 since v-1 blocks are 
given.  Under these conditions, there will be t+j’-k’-k – signs in the response vector.  By 
relabeling indices and summing, the Vandermonde convolution (27) gives 
 for k=1,…,t-1 and j=1,…,t-k.  Thus, summing u from j 
( )
( )
k j
u j
k j t k j t
k j u k k j u k


                  
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to k+j over the different possible sets of v blocks is  - (v-1).  A recursive relationship 
t
k
   
between combinations is  where b=  but  ( 1)
1
b b b v
v v v
               
t
k
    , 21 1
t k
j v
j
b
C
v



    
since all coefficients must sum to the appropriate binomial coefficients and so 
.  Finally, since , 2
1
( )
( 1) ( )
( )
k jt k
j v
j u j
b k j t k j
C v I j u v
v k j u k k j u


 
                              
 ,  Cuv = .,
11
t k
j v
j
b
C
v


     
1
, 1
1
( )
( ) ( 1)
( )
k
j v
j
k j t k j
C vI j u v
j k u k j k u



                    
R Program to group specimens to pools
## install.packages("crossdes")
## install.packages("ibd")
## run under R version 3.4.4 
library(crossdes)
library(ibd)
## Enter number of specimens below (use real integers)
NumberOfSpecimens <- 10
## randomize specimens. We assume your specimens are labeled with letters 
randomSpecimens <- rbind ( sample ( seq ( 1 : NumberOfSpecimens ) , size = 
NumberOfSpecimens , replace = F , prob = NULL ) , seq ( 1 : NumberOfSpecimens ) )
rownames ( randomSpecimens ) <- c ( "your_specimen_ID" , 
"number_ID_assigned_to_Pool_Matrix" )
randomSpecimens
## example: your specimen (1) in row 1 will be assigned to corresponding number in row 2 
given by (randomSpecimens)... and so on
## row2 numbers correspond to numbers in (Pool_Matrix) below
## the example below refers to: 5 choose 2 = NumberOfSpecimens
A = find.BIB ( 5 , NumberOfSpecimens , 2 )
N = design_to_N ( A ) 
numRows <- dim ( N ) [ 1 ]
numCols <- dim ( N ) [ 2 ]
colnames ( N ) <- seq ( 1 , numCols )
rownames ( N ) <- seq ( 1 , numRows )
specimensAll <- NULL
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for ( i in 1 : dim ( N ) [ 1 ] ) {
  temp1 <- N [ i , N [ i , ] %in% c ( 1 ) ]
  specimensAll <- rbind ( specimensAll , names ( temp1 ) )
}
Pool_Matrix <- t ( specimensAll )
colnames ( Pool_Matrix ) <- paste ( "Pool" , seq ( 1 , dim ( Pool_Matrix ) [ 2 ] ) , sep = "_" )
Pool_Matrix
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